Drug data last refreshed 2d ago · AI intelligence enriched 2w ago
HYDROCORTONE (hydrocortisone sodium phosphate) is an injectable corticosteroid approved in 1960 for rapid anti-inflammatory and immunosuppressive effects. It is administered intravenously or intramuscularly for acute inflammatory and allergic conditions requiring systemic corticosteroid therapy. The drug works by suppressing the immune response and reducing inflammation across multiple organ systems.
Product is in late-lifecycle stage with moderate competitive pressure (30), indicating a mature team focused on defending market share against generics and alternatives rather than growth initiatives.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Working on HYDROCORTONE offers limited career growth opportunities given its approaching loss of exclusivity and mature market position. Roles focus on defending existing market share, managing generic competition, and optimizing operational efficiency rather than expansion or innovation.
Worked on HYDROCORTONE at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/mo